Senores Pharmaceuticals Limited — Others, 23-07-2025: Appointment

Senores Pharmaceuticals announced its Q1 FY26 financial results. Consolidated total income surged to Rs 138 Cr, up 72% year-over-year, with EBITDA at Rs 34.2 Cr (+60% YoY) and PAT at Rs 21.2 Cr (+95% YoY). The company's board also approved the appointment of Mr. Jignesh Shashikant Desai as President-Finance, bringing over 30 years of finance expertise. Operational highlights include strong growth in Regulated Markets revenue, reaching Rs 90 Cr, and positive operating cash flow of Rs 11 Cr for the quarter. Management is focused on expanding its ANDA portfolio and scaling CDMO/CMO in regulated markets, along with improving profitability in emerging markets.